Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand.
Department of Molecular Medicine and Pathology and Bioinformatics Institute, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand; Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand.
Biochem Pharmacol. 2014 May 15;89(2):224-35. doi: 10.1016/j.bcp.2014.03.001. Epub 2014 Mar 13.
The nitro-chloromethylbenzindoline prodrug SN29428 has been rationally designed to target tumour hypoxia. SN29428 is metabolised to a DNA minor groove alkylator via oxygen-sensitive reductive activation initiated by unknown one-electron reductases. The present study sought to identify reductases capable of activating SN29428 in tumours. Expression of candidate reductases in cell lines was modulated using forced expression and, for P450 (cytochrome) oxidoreductase (POR), by zinc finger nuclease-mediated gene knockout. Affymetrix microarray mRNA expression of flavoreductases was correlated with SN29428 activation in a panel of 23 cancer cell lines. Reductive activation and cytotoxicity of prodrugs were measured using mass spectrometry and antiproliferative assays, respectively. SN29428 activation under hypoxia was strongly attenuated by the pan-flavoprotein inhibitor diphenyliodonium, but less so by knockout of POR suggesting other flavoreductases contribute. Forced expression of 5-methyltetrahydrofolate-homocysteine methyltransferase reductase (MTRR), as well as POR, increased activation of SN29428 in hypoxic HCT 116 cells. SN29428 activation strongly correlated with expression of POR and also FAD-dependent oxidoreductase domain containing 2 (FOXRED2), in cancer cell lines. This association persisted after removing the effect of POR enzyme activity using first-order partial correlation. Forced expression of FOXRED2 increased SN29428 activation and cytotoxicity in hypoxic HEK293 cells and also increased activation of hypoxia-targeted prodrugs PR-104A, tirapazamine and SN30000, and increased cytotoxicity of the clinical-stage prodrug TH-302. Thus this study has identified three flavoreductases capable of enzymatically activating SN29428, one of which (FOXRED2) has not previously been implicated in xenobiotic metabolism. These results will inform future development of biomarkers predictive of SN29428 sensitivity.
硝基氯甲基苯并吲哚啉前药 SN29428 经过精心设计,可靶向肿瘤缺氧。SN29428 通过未知的单电子还原酶启动的氧敏感还原激活,代谢为 DNA 小沟烷化剂。本研究旨在鉴定能够在肿瘤中激活 SN29428 的还原酶。使用强制表达和锌指核酸酶介导的基因敲除(POR)调节候选还原酶在细胞系中的表达。使用质谱法和增殖抑制测定法分别测量前药的还原激活和细胞毒性。缺氧下 SN29428 的激活被泛黄素蛋白抑制剂二苯基碘鎓强烈减弱,但 POR 敲除时减弱较少,表明其他黄素还原酶也有贡献。在缺氧的 HCT 116 细胞中,强制表达 5-甲基四氢叶酸-同型半胱氨酸甲基转移酶还原酶(MTRR)以及 POR 均可增加 SN29428 的激活。SN29428 的激活与癌症细胞系中 POR 和 FAD 依赖性氧化还原酶结构域包含 2(FOXRED2)的表达强烈相关。在用一阶偏相关去除 POR 酶活性的影响后,这种相关性仍然存在。在缺氧的 HEK293 细胞中,强制表达 FOXRED2 可增加 SN29428 的激活和细胞毒性,还可增加缺氧靶向前药 PR-104A、替拉扎胺和 SN30000 的激活,并增加临床阶段前药 TH-302 的细胞毒性。因此,本研究鉴定了三种能够酶促激活 SN29428 的黄素还原酶,其中一种(FOXRED2)以前未被牵连到外来生物代谢中。这些结果将为 SN29428 敏感性的生物标志物的未来开发提供信息。